Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ: DARE) reported Q3 2025 results and a corporate update announcing near-term commercialization plans and continued clinical progress.
Key points: DARE to PLAY™ Sildenafil Cream on track for initial prescription fulfillment in December via a 503B outsourcing facility; Ovaprene® Phase 3 received a positive interim DSMB recommendation and enrollment continues; multiple grant-funded programs advanced (DARE-HPV, DARE-LARC1, DARE-NHC) with recent grant installments totaling $10 million and an anticipated $3.6 million installment in November 2025. Financials: $23.1M cash, $3.8M working capital, Q3 G&A $2.5M, R&D $1.2M.
Daré Bioscience (NASDAQ: DARE) will host a live webinar on November 17, 2025 to review clinical data and commercial launch readiness for DARE to PLAY™ Sildenafil Cream, a first-of-its-kind topical sildenafil formulation for women. Clinical results cited show increased genital blood flow within 10–15 minutes of application and improvements in arousal on clinically validated, FDA-reviewed endpoints. The company said commercial availability is anticipated via a 503B outsourcing facility, expected before year-end, and webinar attendees can join a product alert list to be notified when the prescription product becomes available.
Daré Bioscience (NASDAQ: DARE) will host a third quarter 2025 financial results conference call and live webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to review results for the quarter ended September 30, 2025 and provide a company update.
Participants can join by phone at (646) 307-1963 or (800) 715-9871 (toll-free) with conference ID 5794075. The live webcast is available in the Investors > Presentations, Events & Webcasts section at http://ir.darebioscience.com. The webcast archive will be available for replay through November 27, 2025. Attendees are advised to log in 5-10 minutes early to register and install any required software.
Daré Bioscience (NASDAQ: DARE) announced on November 3, 2025 that it has a contract with the Gates Foundation to receive up to $300,000 to conduct a global strategic landscape assessment of organizations with capabilities relevant to contraceptive product development.
Under the contract Daré will identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products. The project is presented as part of Daré’s effort to strengthen the contraceptive innovation ecosystem and identify potential strategic partners to accelerate product translation.
Daré Bioscience (NASDAQ: DARE) received a $4.0 million non-dilutive grant installment on Oct 6, 2025 for DARE-LARC1, the contraception use case of its programmable DARE-IDDS implantable drug-delivery platform. Total grant funding received is approximately $41.8 million of an up-to-approximately $49 million commitment, with up to $7.1 million remaining contingent on milestones. DARE-LARC1 is preclinical and uses levonorgestrel; the platform is described as capable of programmable, wireless dosing and is being explored for obesity, diabetes, and other chronic conditions. Daré is pursuing strategic partnerships and IND-enabling studies toward an FDA IND submission.
Daré Bioscience (NASDAQ: DARE) has secured a grant of up to $499,000 from the Gates Foundation to support preeclampsia research initiatives. The company will provide strategic mentorship and project management support to Grand Challenges grantee organizations worldwide, focusing on prevention, diagnosis, and treatment of preeclampsia.
The multi-year engagement aims to advance research addressing this critical maternal health condition that claims approximately 76,000 maternal and 500,000 infant lives annually. Currently, there are no FDA-approved treatments for preeclampsia, making this initiative particularly significant for advancing women's health solutions.
Daré Bioscience (NASDAQ:DARE) reported Q2 2025 financial results and provided significant updates on its women's health product pipeline. The company is preparing to launch DARE to PLAY™ Sildenafil Cream in Q4 2025 through a 503B compounding pathway, marking its first revenue-generating product. The company reported $5.0 million in cash with a working capital deficit of $12.6 million, but strengthened its position post-quarter with $17.6 million from stock sales and a $6.0 million grant.
Key developments include positive interim results for Ovaprene® Phase 3 study, advancement of grant-funded programs for HPV treatment and long-acting contraception, and plans to commercialize vaginal probiotics and hormone therapy products. R&D expenses decreased 71% year-over-year to $1.4 million, while G&A expenses remained stable at $2.4 million.
Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health solutions, has scheduled its Q2 2025 financial results conference call and webcast for August 14, 2025 at 4:30 p.m. ET.
Investors can join via phone at (646) 307-1963 or toll-free at (800) 715-9871 using conference ID 2684883. The webcast will be available on the company's investor relations website and archived until August 28, 2025.
Daré Bioscience (NASDAQ: DARE) and Rosy Wellness have announced the launch of a consumer awareness campaign for DARE to PLAY™ Sildenafil Cream, a groundbreaking topical formulation for women's arousal targeted for prescription availability in Q4 2025.
The campaign leverages Rosy's platform of 250,000+ women and includes an Arousal Collection and educational "Quickie" videos featuring expert Dr. Sameena Rahman. The product contains sildenafil (Viagra's active ingredient) and is clinically proven to improve genital blood flow and sexual response. This collaboration marks the first phase of a broader initiative that will include healthcare provider awareness and customer support programs.
DARE to PLAY™ will be available as a compounded drug under Section 503B of the FDCA, representing a significant advancement in women's sexual health treatment backed by clinical evidence.
Daré Bioscience (NASDAQ: DARE) announced a live webinar scheduled for August 6, 2025, to showcase DARE to PLAY™, their innovative sildenafil cream for female sexual arousal. The product, containing the same active ingredient as Viagra®, is the first and only evidence-backed sildenafil cream formulation for women, designed to improve genital blood flow and sexual response.
The webinar will feature prominent sexual health experts, including Dr. Irwin Goldstein, discussing clinical evidence and the product's proprietary formulation. DARE to PLAY™ is expected to be available by prescription in Q4 2025. The event, hosted in collaboration with The National Association of Nurse Practitioners in Women's Health, is open to clinicians, investors, and women interested in science-based sexual health solutions.